- Home
- ZVIA vs SLS Comparison
ZVIA vs SLS Comparison
Compare ZVIA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZVIA | SLS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4M | 208.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZVIA | SLS |
|---|---|---|
| Price | $2.61 | $2.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $4.89 | ★ $7.00 |
| AVG Volume (30 Days) | 816.1K | ★ 4.8M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $162,849,000.00 | N/A |
| Revenue This Year | $7.60 | N/A |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $1.88 | $0.83 |
| 52 Week High | $4.99 | $2.48 |
Technical Indicators
Market Signals| Indicator | ZVIA | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 72.75 |
| Support Level | $2.54 | $1.92 |
| Resistance Level | $2.68 | $2.31 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 63.69 | 99.21 |
Price Performance
Historical ComparisonAbout ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.